Pfizer to Replace Migraine-Drug Packaging Over Child-Safety Issues -- Update
2023年3月17日 - 02:48AM
Dow Jones News
By Will Feuer
Pfizer Inc. is developing new packaging for its Nurtec ODT
prescription drug after the U.S. Consumer Product Safety Commission
found the packaging wasn't child-resistant and issued a recall
The commission earlier Thursday issued a recall alert for the
migraine medication, urging consumers to secure the product out of
sight and reach of children and to contact Pfizer for a free
child-resistant pouch to store the product. Pfizer said customers
don't need to return the drug.
"Patients should rest assured that there are no quality or
safety issues nor health risks when they take the medicine as
prescribed for its approved use," Pfizer said.
No incidents or injuries tied to the product have been reported,
the commission said.
Nurtec ODT is manufactured by Biohaven Pharmaceutical Holding
Co. Ltd., which Pfizer bought in October last year. The commission
said its alert applies to 75-milligram, orally disintegrating
Nurtec ODT tablets that are sold in cartons containing one blister
card of 8 tablets.
The commission said the packaging issue affects about 4.2
million units of Nurtec ODT and likely an estimated 300,000 more
units currently out in the marketplace.
As an interim measure, Pfizer has instructed pharmacists to
place the non-child-resistant blister in a child-resistant vial
prior to dispensing the medication to patients.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
March 16, 2023 13:33 ET (17:33 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
から 5 2023 まで 6 2023
から 6 2022 まで 6 2023